Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients Life Science Investing
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors Life Science Investing
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid, Triggering a $25 Million Milestone Payment Life Science Investing
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update Life Science Investing
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update Life Science Investing
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Life Science Investing
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Life Science Investing
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance Pharmaceutical Investing
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months Psychedelics Investing
